Abstract
The mechanisms of infection and immunity in pertussis are not well understood, and as a result, the development of a new, improved vaccine is difficult. This paper describes the limitations of currently available vaccines, and outlines the problems associated with the introduction of new prophylactics, such as defining the bases of toxicity and efficacy and organizing meaningful clinical trials. Until these problems are resolved, efforts are needed to improve currently available whole-cell vaccines. The possible role of passive immunity in the control of the disease is also discussed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Imagawa T., Sonoda S., Kanoh M., Utsumi S. Polymorphonuclear leukocyte-inhibitory factor of Bordetella pertussis. II. Localization in the outer membrane. Biken J. 1979 Mar;22(1):1–10. [PubMed] [Google Scholar]
- Kabat Elvin A. Ethics and the wrong answer. Science. 1975 Aug 15;189(4202):505–505. doi: 10.1126/science.11643278. [DOI] [PubMed] [Google Scholar]
- Utsumi S., Sonoda S., Imagawa T., Kanoh M. Polymorphonuclear leukocyte-inhibitory factor of Bordetella pertussis. I. Extraction and partial purification of phagocytosis- and chemotaxis-inhibitory activities. Biken J. 1978 Dec;21(4):121–135. [PubMed] [Google Scholar]